Biologic Therapy

Apremilast's primary significance over injectable biologics is its oral administration route, which substantially improves patient acceptance. Correcting the percentage of prior biologic therapy use ensures proper characterization of the trial population's treatment history. In the omalizumab and benralizumab subgroup of 67 patients, 2 patients had prior HES-related biologic therapy in the preceding 12 months. All biologic treatments suppress the immune pathways driving psoriasis without addressing root causes, and patients typically relapse upon discontinuation. Adalimumab carries a well-documented paradoxical risk of inducing de novo psoriasis when administered for Crohn's disease.